Information Provided By:
Fly News Breaks for September 13, 2017
Sep 13, 2017 | 08:29 EDT
Citi analyst Liav Abraham cut her price target for Synergy Pharmaceuticals to $2.50 and reiterates a Sell rating on the shares. The intellectual property on the company's lead compound, Trulance, expires in 2032, which, in the absence of life-cycle management programs, implies "minimal terminal value of the company over the longer term," Abraham tells investors in a research note. The analyst says that even with the stock's underperformance this year, she still struggles to become more constructive on the name.
News For SGYP From the Last 2 Days
There are no results for your query SGYP
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.